{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-086937","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.957590+00:00","generated_at":"2026-06-08T03:19:41.008059+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CorMedix Q3 net loss $9.7M; FDA inspections complete, launch targeted by Q1 2024","bullets":["Net loss $9.7M ($0.17/sh) vs $6.9M ($0.17/sh) in Q3 2022; operating expenses up 50% to $10.5M.","Cash and short-term investments $86.6M as of Sept 30, 2023; sufficient for at least 12 months.","FDA completed preapproval inspections at primary CMO and key suppliers; no known deficiencies.","USPTO issued patent for DefenCath composition-of-matter (expiry April 2042).","Commercial launch targeted before end of Q1 2024 if FDA approval received."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-086937","json":"https://secwatch.observer/filing/0001213900-23-086937.json","markdown":"https://secwatch.observer/filing/0001213900-23-086937.md","text":"https://secwatch.observer/filing/0001213900-23-086937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/0001213900-23-086937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/ea188304-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:19:41.008059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d4e759544f361d1ac692e9dfb855b33dbec038b","claim":"CorMedix Inc. reported nine months ended September 30, 2023 results: net income net loss of $31.6 million, or $0.65 per share, EPS $0.65 per share.","evidence_excerpt":"For the nine months ended September 30, 2023, CorMedix recorded a net loss of $31.6 million, or $0.65 per share, compared with a net loss of $21.5 million, or $0.54 per share, in the first nine months of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/0001213900-23-086937-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Net income","value":"net loss of $31.6 million, or $0.65 per share"},{"label":"EPS","value":"$0.65 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e47d9ce6feff9f1d037982ad84a7ffeabf335731","claim":"CorMedix Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.7 million, or $0.17 per share, EPS $0.17 per share.","evidence_excerpt":"For the third quarter of 2023, CorMedix recorded a net loss of $9.7 million, or $0.17 per share, compared with a net loss of $6.9 million, or $0.17 per share, in the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/0001213900-23-086937-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $9.7 million, or $0.17 per share"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}